Telix Pharmaceuticals Limited
TLX evidence brief
What we can confirm
- BioSniper Score:
- 6.2 / 10
- Market Cap:
- $3.99B
- Lead Asset:
- illuccix (Approved)
What it means
What to watch
Prepared research question
What matters most for TLX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TLX
Telix Pharmaceuticals Limited (TLX) is an Australian radiopharmaceutical company focused on developing and commercializing targeted radionuclide therapies and diagnostics for oncology, with a commercial portfolio anchored by Illuccix and Gozellix and a late-stage pipeline in prostate, renal, and brain cancers.
Key risk: Legal and SEC risks
BioSniper Score
Based on 4 of 6 signals
Tracking 2 pipeline candidates · 1 catalyst · 2 FDA decisions for Telix Pharmaceuticals Limited.
Telix Pharmaceuticals Limited (TLX) is an Australian radiopharmaceutical company focused on developing and commercializing targeted radionuclide therapies and diagnostics for oncology, with a commercial portfolio anchored by Illuccix and Gozellix and a late-stage pipeline in prostate, renal, and brain cancers.
- Telix reported FY2026 revenue guidance of $950–$970 million and Q1 2026 revenue of $230 million [news · published 2026-05-18].
- The company received FDA approval for PIXCLARA in 2026 and has multiple Phase 3 trials underway, including LUTEON for ccRCC and IPAX BrIGHT for glioblastoma [news · published 2026-09-16][news · published 2026-07-20].
- R&D spending increased by 47% in 2025, supporting pipeline progress in prostate and brain cancer trials [news · published 2025-09-18].
- Telix dosed the first patient in the Phase 3 LUTEON trial of TLX250-Tx for renal cancer in July 2026 [news · published 2026-07-20].
What works
- Commercial-scale franchises (Illuccix, Gozellix) generate recurring revenue that funds pipeline development [news · published 2026-07-31].
- Strong revenue growth trajectory: 27% year-over-year growth and FY2026 guidance of $950–$970 million [news · published 2026-09-16][news · published 2026-08-24].
- Multiple Phase 3 trials in high-value oncology indications (prostate, renal, glioblastoma) de-risk pipeline [news · published 2026-07-20][catalyst].
- FDA approval of PIXCLARA in 2026 adds a new approved diagnostic product [news · published 2026-09-16].
What to weigh
- Legal and SEC risks are noted as potential overhangs [news · published 2026-08-24].
- R&D spending increased 47% in 2025, which may pressure near-term profitability [news · published 2025-09-18].
- Pipeline is heavily weighted toward early-stage and Phase 3 trials that have not yet generated revenue from therapeutic products [catalyst].
- Patent expiry for GALLIUM GA-68 GOZETOTIDE is scheduled for 2035-07-28, which could eventually affect one product's exclusivity [catalyst].
From the filings
Quoted directly from source documents.
Telix dosed first patient in Phase 3 LUTEON trial for renal cancer
“Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announced that the first patient has been dosed with TLX250-Tx (lutetium-177 (177Lu) girentuximab tetraxetan) in the LUTEON study, the first radiopharmaceutical therapy to enter Phase 3 development for ccRCC.”
News · July 20, 2026
Telix received FDA approval for PIXCLARA in 2026
“Telix Pharma stays a Buy after FDA approval of PIXCLARA, strong oncology pipeline progress, and 27% YoY revenue growth.”
News · September 16, 2026
R&D spending increased by 47% in 2025
“Telix Pharmaceuticals Limited (TLX) Increases R&D by 47%, Progresses Key Prostate and Brain Cancer Trials”
News · September 18, 2025
Catalyst timeline
- 2035-07-28 · Patent_Expiry · GALLIUM GA-68 GOZETOTIDE — Patent expiry for NDA214032; may affect exclusivity of the product.
Risks & what to watch (4)›
Key risks
- Legal and SEC risks — Legal/SEC risks are noted as potential overhangs for the company [news · published 2026-08-24].
- R&D cost pressure — 47% R&D increase in 2025 may pressure near-term profitability [news · published 2025-09-18].
- Pipeline revenue lag — Therapeutic pipeline is still in Phase 3 and not yet generating product revenue [catalyst].
- Patent expiry — Patent expiry for GALLIUM GA-68 GOZETOTIDE on 2035-07-28 could affect exclusivity [catalyst].
What to watch
- Progress of Phase 3 LUTEON trial for TLX250-Tx in renal cancer [news · published 2026-07-20].
- Commercial uptake of newly approved PIXCLARA [news · published 2026-09-16].
- Execution on FY2026 revenue guidance of $950–$970 million [news · published 2026-08-24].
- Outcome of legal/SEC matters [news · published 2026-08-24].
Sources: Catalysts · News · Generated October 12, 2026 · How we verify sources →
Run Telix Pharmaceuticals Limited through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Telix Pharmaceuticals Limited facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
2 candidates
1 upcoming, next in ~3208d
2 buys · 0 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
38
Total value held
$24.5M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 564,757 | $5.4M |
| portolan capital management, llc | 541,267 | $5.2M |
| lazard asset management llc | 289,917 | $2.8M |
| portland investment counsel inc. | 266,200 | $2.5M |
| private advisor group, llc | 174,415 | $1.7M |
| integrated wealth concepts llc | 164,397 | $1.6M |
| raiffeisen bank international ag | 130,000 | $1.2M |
| morgan stanley | 116,440 | $1.1M |
| jpmorgan chase & co | 57,348 | $514K |
| mariner, llc | 43,446 | $415K |
Showing top 10 of 38 institutional holders of Telix Pharmaceuticals Limited. Open the full 13F history after sign-in.
Short Interest
as of May 1, 2026- % of float
- 0.1%
- Days to cover
- 1.5
- Shares short
- 390,717
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TLX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Telix Pharmaceuticals Limited?
Telix Pharmaceuticals Limited (TLX) is an Australian radiopharmaceutical company focused on developing and commercializing targeted radionuclide therapies and diagnostics for oncology, with a commercial portfolio anchored by Illuccix and Gozellix and a late-stage pipeline in prostate, renal, and brain cancers.
What is Telix Pharmaceuticals Limited's lead drug candidate?
Telix Pharmaceuticals Limited's most advanced tracked candidate is illuccix (Approved).
What is Telix Pharmaceuticals Limited's next catalyst?
Telix Pharmaceuticals Limited's next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA214032" — expected July 28, 2035.
Who is the CEO of Telix Pharmaceuticals Limited?
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.D is the chief executive officer of Telix Pharmaceuticals Limited (TLX).
Where is Telix Pharmaceuticals Limited headquartered?
Telix Pharmaceuticals Limited (TLX) is headquartered in North Melbourne, VIC, Australia.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.